Company Overview and News

 
Immunovaccine to Present at Bloom Burton & Co. Healthcare Investor Conference

4h globenewswire
HALIFAX, Nova Scotia, April 23, 2018 (GLOBE NEWSWIRE) -- Immunovaccine Inc. (TSX:IMV) (OTCQX:IMMVF), a clinical stage immuno-oncology company, announced that Chief Executive Officer Frederic Ors will present an update on the Company's recent progress and future strategy at the Bloom Burton & Co. Healthcare Investor Conference 2018 in Toronto, Canada.
Upvote Downvote

 
Biotech Analysis Central Pharma News: Biogen's Deal, Eli Lilly Partner Incyte Refile Baricitinib, Argos Loses Out

4h seekingalpha
Welcome to Biotech Analysis Central Daily News, a daily news report and analysis about what has happened lately in the biotech industry.
Upvote Downvote

 
Lilly (LLY) to Report Q1 Earnings: What's in the Cards?

2018-04-20 zacks
Eli Lilly and Company (LLY - Free Report) will report first-quarter 2018 results on Apr 24, before market opens. Last quarter, the company delivered a positive earnings surprise of 5.56%.
Upvote Downvote

 
Will the FDA Shoot Down Eli Lilly and Incyte Again?

2018-04-20 247wallst
Incyte Corp. (NASDAQ: INCY) and Eli Lilly and Co. (NYSE: LLY) will be under the microscope next week as the U.S. Food and Drug Administration (FDA) will decide the fate of their rheumatoid arthritis (RA) treatment.
Upvote Downvote

 
Eli Lilly Olumiant Resurrection Story Has Holes - Bloomberg

2018-04-19 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
Upvote Downvote

1
Index of U.S. leading economic indicators up 0.3% in March

2018-04-19 feeds.marketwatch
Consumer-staples stocks sank on Thursday, putting it on track for its biggest decline in more than two months. The sector lost 2.6%, its biggest one-day percentage drop since Feb. 5. By far, the biggest decliner in the sector was Philip Morris International Inc. , which... Full Story
Upvote Downvote

 
FDA staff cites safety issues for Lilly, Incyte's rheumatoid arthritis drug

2018-04-19 channelnewsasia
The U.S. Food and Drug Administration staff on Thursday flagged concerns about potentially fatal blood clots from higher doses of Eli Lilly and Co and Incyte Corp's rheumatoid arthritis drug.
Upvote Downvote

1
FDA staff cites safety issues for Lilly, Incyte's rheumatoid arthritis drug

2018-04-19 reuters
(Reuters) - The U.S. Food and Drug Administration staff on Thursday flagged concerns about potentially fatal blood clots from higher doses of Eli Lilly and Co and Incyte Corp’s rheumatoid arthritis drug.
Upvote Downvote

 
Merus to Report Full Year 2017 Financial Results and Corporate Developments on April 26, 2018

2018-04-19 globenewswire
UTRECHT, The Netherlands, April 19, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced that the Company will report full year 2017 financial results on Thursday, April 26, 2018. Merus’ management team will host a conference call and audio webcast at 8:30 a.m. ET on Thursday, April 26, 2018, to discuss the financial results and recent clinical and corporate developments.
Upvote Downvote

 
Your Daily Pharma Scoop: Blueprint Medicines' BLU-667, Gilead Sciences' NASH Data, Celldex's Plunge

2018-04-17 seekingalpha
Today we will discuss Blueprint Medicines (BPMC), which is down more than 12% after reporting data from a phase 1 study with BLU-667 in RET-altered solid tumors. The phase 1 study was a proof-of-concept study.
Upvote Downvote

 
Immunovaccine Announces Leading Independent Proxy Advisory Firms Recommend Voting for Share Consolidation Related to Potential Nasdaq Listing

2018-04-17 globenewswire
HALIFAX, Nova Scotia, April 17, 2018 (GLOBE NEWSWIRE) -- Immunovaccine Inc. (TSX:IMV) (OTCQX:IMMVF), a clinical stage immuno-oncology corporation, is pleased to announce that Institutional Shareholder Services Inc. (“ISS”) and Glass, Lewis & Co., LLC (“Glass Lewis”), two leading independent proxy advisory firms, have recommended that shareholders vote FOR all items submitted for approbation by the shareholders, including the share consolidation for a potential Nasdaq listing and the Corporation’s name change, at the annual and special meeting of shareholders to be held on May 1, 2018.
Upvote Downvote

2
Days After a Shocking Cancer Failure, Incyte Goes Back to Work - Bloomberg

2018-04-16 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
Upvote Downvote

1
New Preclinical Studies Reinforce the Potential for Heightened Anti-Cancer Activity of Combination Therapies Based on Immunovaccine’s Proprietary Delivery Platform

2018-04-16 globenewswire
HALIFAX, Nova Scotia, April 16, 2018 (GLOBE NEWSWIRE) -- Immunovaccine Inc. (TSX:IMV) (OTCQX:IMMVF), a clinical stage immuno-oncology company, today announced that it presented new research on its T-cell activating platform at the American Association for Cancer Research (AACR) Annual Meeting 2018.
Upvote Downvote

 
The Zacks Analyst Blog Highlights: Agios Pharmaceuticals, BioMarin Pharmaceutical, Vertex Pharmaceuticals and Incyte

2018-04-16 zacks
Chicago, IL – April 16, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Agios Pharmaceuticals, Inc. (AGIO - Free Report) , BioMarin Pharmaceutical Inc. (BMRN - Free Report) , Vertex Pharmaceuticals, Inc. (VRTX - Free Report) and Incyte Corporation (INCY - Free Report) .
Upvote Downvote

1
Incyte's Failure With Merck's Keytruda Has No Implications For OncoSec

2018-04-13 seekingalpha
OncoSec and Merck are pursuing a combination of ImmunoPulse IL-12 with Keytruda in melanoma also, with initial data from a Phase II registrational trial due this year.
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...

CUSIP: 45337C102